First in Human, Dose Escalation, Dose Expansion Study of AUR105

This is an early-phase study testing a new investigational cancer drug called AUR105 for the first time in humans. The study is looking at safe doses and how the drug behaves in the body. It is open to adults with advanced solid tumors or lymphomas that have not responded to standard treatments. **You may be eligible if...** - You are 18 years or older - You have an advanced solid tumor or non-Hodgkin/Hodgkin lymphoma confirmed by biopsy - You have measurable disease and have received at least 2 prior lines of treatment - Your performance status is good (ECOG 0 or 1) - Your blood counts, kidney, and liver function are adequate **You may NOT be eligible if...** - You recently received other cancer treatments or investigational drugs (within 4 weeks or 5 half-lives) - You have active, uncontrolled brain metastases - You have leukemia, myelodysplastic syndrome, or multiple myeloma - You have active HIV, hepatitis B or C, or serious heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.